Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060479 | 0.83 | CHRNA7 (0.45) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL28907062 | 0.83 | GSK3B (0.48) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL6559325 | 0.82 | CHRNA7 (0.49) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL1421391 | 0.81 | CHRNA7 (0.48) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL1421587 | 0.79 | CHRNA7 (0.47) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL1759104 | 0.79 | CHRNA7 (0.49) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL12647211 | 0.77 | CHRNA7 (0.48) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL25515155 | 0.74 | CHRNA7 (0.43) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL25515150 | 0.74 | CHRNA7 (0.43) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL25512171 | 0.74 | CHRNA7 (0.43) | CHRNA7MAPTSMN1; SMN2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | PNMT, HTR5A, HTR4 | CHRNA7 174/4885MAPT 287/4885SMN1; SMN2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.